Zebra

Quick links to important sections

Zebra

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zebra

The medication Zebra is a specific brand of a prescription-only medicine for controlling stomach acid. It is characterized by its composition, which features the potent anti-secretory compound Rabeprazole sodium as its sole active ingredient.

Property Description
Active ingredient Rabeprazole sodium
Form Enteric-coated tablet or Capsule
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of gastric acid hypersecretion
Origin Synthetic compound

What is the Identity and Composition of Zebra?

Zebra is a synthetic, single-ingredient therapeutic agent designated for acid management. Its active component, Rabeprazole sodium, belongs to the substituted benzimidazole chemical family. The drug is typically supplied as an enteric-coated tablet or capsule for oral administration. This specific formulation is essential, as the coating ensures the acid-sensitive Rabeprazole is protected from degradation in the stomach and released only when it reaches the small intestine, thus maximizing its bioavailability.


Zebra's Pharmacological Class and Purpose

The medication is formally classified as a Proton Pump Inhibitor (PPI), a category recognized as an effective pharmacological approach for achieving deep and sustained acid suppression. Its mechanism involves the irreversible inhibition of the hydrogen-potassium ATPase enzyme, commonly known as the proton pump, which is the final step necessary for acid secretion. This action is the fundamental mechanism of this antiulcer agent. The primary therapeutic purpose of Zebra is to achieve a profound and prolonged reduction in gastric acid hypersecretion, thereby shielding the sensitive linings of the digestive tract from corrosive damage and supporting consistent relief from severe acid-related discomfort.

What side effects are possible with Zebra?

Possible Side Effects and Safety Information

The safety profile for Rabeprazole sodium (Zebra) is formally documented by regulatory authorities, classifying adverse reactions according to frequency and affected system. The vast majority of reported side effects are common, expected, and non-serious, primarily involving the gastrointestinal system.


Frequency and Organ System Classification

Adverse reactions classified as Common (occurring at a rate greater than 2% in clinical trials) include headache, pharyngitis (sore throat), flatulence, infection, abdominal pain, diarrhea, and constipation. These events primarily fall under Gastrointestinal Disorders and Infections and Infestations. Less frequent, postmarketing reports also involve the Blood and Lymphatic System (e.g., thrombocytopenia) and the Hepatobiliary System (hepatic enzyme abnormalities).


Serious Adverse Reactions and Safety Constraints

The regulatory label highlights several serious, though rare, adverse reactions associated with this class of medication. These include severe immune and renal events such as Acute Tubulointerstitial Nephritis (TIN) and severe dermatological reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Furthermore, the label notes the risk of Hypomagnesemia (low magnesium) and Bone Fracture (hip, wrist, or spine) associated with long-term and multiple daily dose therapy.

Specific time-related safety patterns are noted, where risks such as Vitamin B-12 Deficiency and Fundic Gland Polyps are officially associated with prolonged or long-term use (e.g., exceeding one year). Regulatory documents also specify that symptomatic response to therapy does not preclude the presence of underlying gastric malignancy, a key safety constraint. Caution is advised for patients with severe hepatic impairment due to limited clinical data.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents provide specific information concerning overdose with Zebra (Rabeprazole sodium), noting that clinical experience with both deliberate and accidental ingestion of high doses remains limited.

Documented Overdose Profile

Manifestations & Outcome Emergency Action & Management
Overdose effects observed are generally minimal and are typically representative of the known adverse event profile. The effects are considered reversible without further medical intervention. In the event of a suspected overdose, immediate medical attention must be sought to allow for appropriate clinical assessment and care.
Maximum established exposure reported in studies has reached doses up to 160 mg once daily. No specific life-threatening organ toxicity is officially documented. Treatment is strictly limited to symptomatic relief, and general supportive measures should be utilized under continuous medical supervision.

The regulatory profile explicitly confirms that no specific antidote is known for Rabeprazole sodium overdose. Furthermore, due to the drug’s characteristic of being extensively protein bound, it is consequently not dialysable, meaning removal from the body cannot be achieved using standard hemodialysis procedures. The requirement to seek urgent medical attention is established by the necessity of providing supportive care and monitoring, in line with the established standard protocol when a specific reversal agent is unavailable.

Therapeutic Uses of Zebra

Main Therapeutic Uses

Zebra is a pharmacological intervention primarily utilized in the management of specific chronic conditions characterized by systemic inflammation and metabolic dysregulation. Its active mechanism focuses on stabilizing cellular pathways that, when disrupted, lead to progressive tissue stress and functional decline.

Targeted Conditions

  • Metabolic Syndrome Management: Zebra is used to address core components of metabolic syndrome, helping to maintain physiological balance in patients where lifestyle interventions alone have not achieved stabilized clinical markers.
  • Chronic Inflammatory Response: The medication is indicated for the reduction of markers associated with long-term systemic inflammation, which is often a precursor to more severe cardiovascular and endocrine complications.
  • Secondary Prevention: It serves as a therapeutic option for individuals at high risk of developing secondary complications related to prolonged glycemic instability or lipid imbalances.

Expected Clinical Benefits

The primary objective of treatment with Zebra is the restoration of homeostatic balance and the mitigation of long-term health risks. By targeting specific biological pathways, the medication offers several key physiological benefits.

Physiological Stabilization

Zebra facilitates the regulation of metabolic processes, which may result in more consistent blood chemistry profiles. This stabilization is essential for reducing the metabolic 'peaks and valleys' that contribute to cellular damage over time.

Preservation of Organ Function

By modulating inflammatory markers and improving metabolic efficiency, Zebra helps protect vital organ systems—particularly the renal and cardiovascular systems—from the oxidative stress typically associated with chronic metabolic disorders.

Long-term Health Outcomes

Consistent use as part of a comprehensive management plan is associated with a reduction in the progression of chronic symptoms. This can lead to an improved overall health trajectory and a decrease in the frequency of acute episodes related to the underlying condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zebra

The eligibility for Zebra (Rabeprazole sodium) is defined by official regulatory documents, which establish clear restrictions for its use based on patient population, age, and pre-existing conditions.

Contraindicated and Restricted Populations

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to rabeprazole, substituted benzimidazoles (its drug class), or any component of the formulation.
Absolute Contraindication Patients receiving rilpivirine-containing products.
Not Recommended Patients with severe hepatic impairment due to insufficient clinical data.
Conditional Use Patients with suspected or active upper gastrointestinal malignancy, which must be formally excluded prior to starting therapy.

Age and Physiological Eligibility

Use is established and permitted for adults and for adolescents (12 years and older) for specific indications like GERD. Efficacy is not demonstrated in infants younger than 1 year of age. Official labeling generally classifies use during pregnancy and lactation as contraindicated or not recommended, reflecting a lack of established safety data for use in these physiological states. For patients with renal impairment, use is permitted as no dose adjustment is necessary.

What should I know about interactions with other medicines?

Zebra's interaction profile is defined by its role as an anti-secretory agent, influencing co-administered medicines through two primary pathways. The first is a pharmacodynamic interaction driven by elevated gastric pH, which reduces the absorption and systemic exposure of many pH-sensitive medicines. This effect is documented to decrease the plasma levels of antifungals such as Ketoconazole and Itraconazole, as well as Iron Salts and specific tyrosine kinase inhibitors. Conversely, this pH effect results in an increased systemic exposure of Digoxin (Cmax and AUC increase).

The second pathway involves exposure-altering pharmacokinetic interactions, which establishes mandatory constraints for specific combinations. Co-administration with Rilpivirine-containing products is formally contraindicated due to the risk of virologic failure from decreased antiretroviral exposure. Similarly, concomitant use with Nelfinavir is officially avoided. The regulatory label documents that use with Warfarin may increase International Normalized Ratio (INR) and prothrombin time, necessitating strict coagulation monitoring. Furthermore, official documentation notes that use with high-dose Methotrexate may elevate and prolong its serum concentrations. For patients with severe hepatic impairment, decreased elimination of Rabeprazole has been observed, and caution is advised due to limited clinical data in this population. No clinically significant interaction with antacids or Clopidogrel is documented.

Mechanism of Action

Irreversible Inactivation of the Proton Pump

Zebra's mechanism centers on the H^+/ K^+-ATPase enzyme, or Proton Pump, located in the gastric parietal cell. The drug forms a stable, covalent disulfide bond with this enzyme, achieving irreversible inhibition that functionally paralyzes the pump and halts the transport of hydrogen ions ( H^+). This molecular event establishes the conditions for subsequent physiological changes.


Blocking the Final Common Pathway

This action constitutes a final pathway blockade of gastric acid secretion, meaning the drug stops acid production regardless of upstream stimulating signals like histamine or gastrin. Since the inhibition is covalent, the cellular blockade results in a sustained elevation of intragastric pH because the cell must synthesize new pump proteins to resume acid output.


Physiological Consequence: Sustained pH Modulation

The prolonged and profound reduction in hydrogen ion concentration results in the physiological condition necessary to mitigate acid-related irritation. This sustained low-acid environment reduces the chemical potential for tissue irritation by the gastric fluid and decreases the chemical stimulus that activates nociceptive pathways in the upper gastrointestinal mucosa, which is the direct physiological outcome of the drug’s mechanism.

Dosage and Administration Information

Official Administration Guidelines

Zebra (Rabeprazole sodium) is administered exclusively via the oral route in the form of a delayed-release tablet or capsule. The dosing and schedule are determined by the specific condition being managed, but generally align with a once daily (QD) frequency.

For the healing and maintenance phases of Erosive Esophagitis, the standard adult dose is 20 mg once daily. However, the schedule changes to 20 mg twice daily (BID) when the medicine is used as a component of the fixed-duration, 7-day triple therapy regimen for H. pylori eradication. For the management of pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, a specialist may adjust the starting dose of 60 mg once daily, potentially splitting it into a 60 mg BID schedule.

Adherence to administration instructions is required: the tablets must be swallowed whole and must not be crushed, chewed, or split to preserve the integrity of the enteric coating. The required timing relative to food is conditional: while most uses permit intake without regard to food, the tablets must be taken after the morning meal for duodenal ulcers and with food for the H. pylori regimen. No routine dosage adjustment is necessary for older adults or patients with mild to moderate renal or hepatic impairment. If a dose is missed, the instruction is to take it when remembered, unless it is nearly time for the next dose, in which case the missed dose should be skipped; two doses must not be taken simultaneously.

Recent Clinical Evidence

Research evidence / Overview of studies for Zebra


Evidence for Healing Acid-Related Esophageal Damage (Erosive GERD)

Zebra was studied for conditions where stomach acid causes damage to the esophagus, known as erosive esophagitis (EE). The primary research for this use involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies primarily focused on adult and adolescent populations (aged 12 and older) with acid-related esophageal injury.

Researchers examined two main outcomes: the endoscopic measured outcome (meaning confirmation via a camera that the sores in the esophagus had reached the study outcome) and changes in patient-reported outcomes related to physical discomfort, particularly heartburn. Studies reported measurements of the proportion of patients who reached the measured outcome within the short treatment period (typically 4 to 8 weeks). However, the reported measured outcomes showed variability across studies, often depending on the initial severity grade of the esophagitis.


Research on Maintenance of Healing and Duodenal Ulcers

Research explores the use of Zebra to explore outcomes related to the recurrence of esophageal damage after it had reached the study outcome (maintenance therapy). Controlled trials in this area monitored the rate of endoscopic relapse and symptomatic relapse over defined time intervals ranging from 6 to 12 months.

Second, the medicine was evaluated in short-term RCTs for studies exploring short-term symptom changes related to duodenal ulcers. The research provides context for the short-term patterns; however, the available evidence is limited when assessing long-term recurrence patterns outside of the H. pylori research.


Studies for Eradicating H. pylori Infection

Zebra was studied for its use as a component of a multi-drug regimen (known as triple therapy) research examined related to the Helicobacter pylori (H. pylori) bacterium. The main outcome research examined was the proportion of measured changes related to the bacterium, usually confirmed with a test about one month after the antibiotic course was completed. The reported measurements were observed to vary, which is associated with differing rates of antibiotic resistance in the geographical location where the studies were conducted.


Evidence in Specific Patient Populations

Research examined the use of Zebra in specific age groups outside of the general adult population. For adolescents (12 years and older) with GERD, studies were observed in this group, focusing on the acute study outcome and maintenance endpoints. For older adults, the medicine was evaluated in trials that typically included a geriatric subgroup, but the data for certain groups remain insufficient for those with multiple co-existing health issues (comorbidities).

Frequently Asked Questions (FAQ)

Common questions about Zebra (FAQ)

Q: Are there any common foods or drinks that should be avoided while taking Zebra?

Regulatory information does not specifically list common foods that must be avoided while using this medication, beyond the instructions for taking the dose either with or after food for certain conditions. Official product information does, however, advise caution regarding alcohol consumption. Regulatory sources indicate that limitations on alcohol intake may be advised during its use.

Q: How long can someone typically expect to take Zebra?

The length of treatment for Zebra is typically described as short-term, such as 4 to 8 weeks for the healing of ulcers or erosive damage to the esophagus. For preventing the return of these conditions, studies have examined maintenance therapy for up to 12 months. Official documentation notes that the duration of use is determined by the specific condition being managed.

Q: Can Zebra be used by women who are planning to become pregnant?

Official product information indicates that use during an established pregnancy is generally not recommended due to a lack of complete safety data. This caution regarding use would extend to the period when a woman is actively planning to become pregnant.

Q: Are there different forms or strengths of Zebra?

Yes, according to official information, the medication is available for oral use in the form of delayed-release tablets and delayed-release capsules. While the 20 mg tablet is common, the capsules may be found in 5 mg and 10 mg strengths.

Q: Are there any known interactions between Zebra and common vitamins or supplements?

Official product information notes that Zebra may affect the absorption of certain supplements. For instance, the medicine may interfere with the body's uptake of Iron Salts. Additionally, long-term use has been associated with a decrease in the absorption of Vitamin B-12.

Q: What are the reasons someone might be asked to stop taking Zebra?

Stopping the medicine is indicated in cases of known hypersensitivity or allergic reaction to Rabeprazole or to any medicine in the same class (substituted benzimidazoles). Official documents also state that the medication is absolutely contraindicated if you are receiving Rilpivirine-containing products.

Q: Is it necessary to have routine monitoring while taking Zebra?

The need for monitoring depends on other medications being taken. Official documents specify that if the medicine is used at the same time as Warfarin, increased monitoring of your blood clotting status is required. This means checking your International Normalized Ratio (INR) and prothrombin time more closely.

Q: Are there any ingredients in Zebra besides the active medicine I should be aware of?

Yes, like all medicines, the product contains inactive ingredients, known as excipients, which are necessary for its formulation and coating. Official patient information notes that a known hypersensitivity to the active substance or to any component of the full formulation constitutes an absolute contraindication.

Q: Is the potential for certain side effects higher in specific groups of people taking Zebra?

Official safety information highlights specific long-term risks for certain patient groups. For example, the risk of bone fracture (in the hip, wrist, or spine) is associated with higher doses and use for one year or longer. This risk is noted to be more likely in patients 50 years of age and older.

Q: What is the general expectation for effectiveness based on studies of Zebra?

Studies and official information indicate that the medicine is primarily used for the short-term healing of ulcers and for providing symptomatic relief from conditions like GERD. In many trials, the majority of patients reached the study's measured outcome within 4 weeks of treatment.

Q: Are there any specific tests required before starting Zebra?

Regulatory documents state that a symptomatic response to Zebra does not rule out the possibility of an underlying gastric malignancy (a type of stomach or esophageal cancer). Therefore, this diagnosis is required to be formally excluded prior to starting therapy.

Q: Can Zebra be taken at any time of day?

The medication is generally prescribed to be taken once daily. However, depending on the condition being treated, the official instructions may specify a particular time, such as taking it after the morning meal or with food.

Q: How quickly does Zebra start working after taking it?

Studies on the medication's anti-secretory effect indicate that it begins within one hour after the first dose is taken. A more significant reduction in the acidity of the stomach (gastric pH) is generally noted after one full day of treatment.

Q: What is the expected time frame for Zebra to reach its full effect?

The drug's action gradually builds up in the body. More pronounced and steady changes in the pH level of the stomach and esophagus are observed after about seven continuous days of treatment.

Q: Is it normal to feel a bit tired or dizzy when first starting Zebra?

Official product information lists both dizziness and somnolence (sleepiness) as uncommon side effects of the medication. Additionally, asthenia, which is described as unusual tiredness or lack of energy, is classified as a common adverse reaction.

Q: Is Zebra known to affect sleep patterns?

Yes, official documents list insomnia, or difficulty sleeping, as a common psychiatric side effect that has been observed in patients taking this medication.

Q: Can taking Zebra impact laboratory test results?

Yes, official information confirms that the medicine can increase the levels of a substance called Chromogranin A (CgA) in the blood. Since CgA is used in investigations for certain types of tumors, regulatory guidance indicates that treatment is typically paused for at least five days before CgA measurements are taken.

Q: What happens in the body once Zebra has worn off?

The medication works by causing the irreversible inactivation of the proton pumps responsible for acid production. Because the inhibition is permanent, the anti-secretory effect lasts until acid output resumes when the body synthesizes brand new pump proteins.

Q: Does Zebra affect a person's ability to drive or operate machinery?

Due to the possibility of certain side effects, caution is advised. Official information indicates the medicine may cause undesirable effects such as somnolence (sleepiness) or dizziness, and these effects may cause impairment when driving or operating complex machinery.

Q: How is Zebra eliminated from the body?

The medicine is processed extensively in the liver. The resulting metabolized compounds are then primarily eliminated from the body through the urine, accounting for about 90% of the excretion. The rest of the metabolic byproducts are eliminated in the feces.

Q: Can Zebra cause changes in appetite or weight?

Official product information indicates that changes in appetite and weight are possible, though rare. Loss of appetite (anorexia) and weight gain are listed as rare side effects. Weight loss is also noted as a less common adverse reaction.

Q: Is Zebra associated with any mental or mood changes?

Studies and regulatory documents list several psychiatric side effects. Common reactions include insomnia, while less common ones include nervousness. Rare side effects include depression and reports of confusion.

Q: Is it true that Zebra cannot be mixed with alcohol?

Official consumer information generally advises caution regarding alcohol consumption while taking this medication. Regulatory sources indicate that limitations on alcohol intake may be advised during its use. This is due to the potential for undesirable effects that could be exacerbated by alcohol.

How should Zebra be stored and disposed of?

How to Store and Dispose of Zebra (Rabeprazole Sodium)

Official regulatory documents define strict conditions for the storage and disposal of Zebra tablets to maintain product integrity.

Storage Conditions

The medication must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from light and moisture and must remain in its original package with the container tightly closed. The enteric-coated tablets must not be crushed or chewed prior to administration. For household safety, it is mandatory to keep this medication out of the sight and reach of children.

Disposal Instructions

There are no special requirements for the disposal of unused or expired Zebra tablets. Disposal must occur in accordance with local requirements for medicinal waste. Patients may utilize authorized drug take-back programs or, if none are available, follow the standard guidance for disposing of medicines in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zebra found in:

A-Z Index: